Hyderabad, Feb 25 (Maxim News): Hyderabad-based Biological E. Limited (BE) announced a strategic partnership with Denmark-based Bavarian Nordic A/S to expand access to Bavarian Nordic’s Chikungunya Vaccine in low- and middle-income countries (LMICs).
As part of the agreement, there will be a technology transfer of the current drug product manufacturing process for the Chikungunya vaccine. There is also an option to transfer the drug substance process at a later stage. This collaboration aims to increase manufacturing capacity and ensure future vaccine supplies for endemic LMICs.
Following the initial technology transfer, regulatory approval applications will be submitted, with commercial manufacturing set to commence thereafter.
BE plans to upgrade its existing facilities in Genome Valley, Hyderabad to support vaccine production. This expansion is expected to create up to 300 new jobs, according to a press release.
Leaders Speak on the Partnership
Mahima Datla, Managing Director of Biological E. Limited, stated:
“Our manufacturing scale and proven track record in providing global vaccine access align synergistically with Bavarian Nordic through this strategic partnership.”
Paul Chaplin, President and CEO of Bavarian Nordic, emphasized the importance of this collaboration:
“Expanding supply is essential to meet the growing demand for effective solutions to prevent Chikungunya in vulnerable populations across endemic regions. We are committed to building strong partnerships to help achieve this goal.”
About the Vaccine
The CHIKV VLP is an adjuvanted VLP recombinant protein vaccine designed for active immunization against Chikungunya virus (CHIKV) in individuals aged 12 years and older. Since the vaccine contains no viral genetic material, it cannot infect cells, reproduce, or cause disease.
In February 2025, the U.S. Food and Drug Administration (USFDA) approved VIMKUNYA (CHIKV VLP), marking it as the first Chikungunya vaccine authorized for individuals aged 12 and above. The approval was based on the results of two Phase 3 clinical trials involving over 3,500 healthy participants aged 12 and older. (Maxim News)
More Stories…
Osmania University Clarifies Stance On Bakrid Exam Schedule
Osmania University announced that no exams are slated for May 27 due to Bakrid, adding that schedules will shift if the moon sighting changes the festival date.
Asaduddin Owaisi Urges Government To Postpone OU Examinations
AIMIM chief Asaduddin Owaisi requested the Telangana government to postpone Osmania University examinations scheduled on May 28 due to Eid al-Adha.
Gold Rates Sees A Fall In Hyderabad On 18 May, 2026
he gold rates today in Hyderabad on 18 May, 2026. Going by the rates today, the price of 10 grams of 22-carat gold is Rs. 1,43,200 with a fall of Rs. 650 while the rate of 10 grams of 24-carat gold is at Rs 1,56,220 with a fall of Rs. 710. While the Silver rate…
Now you can get the latest stories from Indtoday on Telegram every day. Click the link to subscribe. Click to follow Indtoday’s Facebook page, Twitter and Instagram. For all the latest Hyderabad News update
